A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jing wang
Hunan Cancer Hospital
Principal Investigator - LingYIng Wu
The Cancer Hospital of the Chinese Academy of Medical Sciences
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Gcp Center for Anticancer Drugs,the Independent Ethics Committee
Beijing, Beijing Municipality, China
Recruiting - the Cancer Hospital of the Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Recruiting - Hunan Cancer Hospital
Hunan, Changsha, China
Recruiting - Fujian Cancer Hospital
Fuzhou, Fujian, China
Recruiting - Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Recruiting - Yuebei People'S Hospital
Shaoguan, Guangdong, China
Recruiting - the First Affiliated Hospital of Guilin Medical Universty
Guilin, Guangxi, China
Recruiting - Liuzhou Workers' Hospital
Liuzhou, Guangxi, China
Recruiting - Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Recruiting - the People'S Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
Recruiting - Henan Cancer Hospital
Zhengzhou, Henan, China
Recruiting - the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Recruiting - the First Affiliated Hospital of Xi'An Jiaotong University
Xi’an, Shanxi, China
Recruiting - Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Recruiting - Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Oct 2021
- Primary completion
- 7 Nov 2029
- Completion
- 7 Nov 2029
- Last update posted
- 6 Feb 2026
- Registered enrollment
- 228
- Registry id
- NCT07392736
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.